Gene therapy for blinding retinal disease hits FDA-aligned endpoint in every patient; Phase 3 bet now hinges on whether a small randomized trial replicates it

Opus Genetics is a clinical-stage gene therapy company developing a treatment for a rare blinding inherited retinal disease; the lead program is not yet approved, though early-phase results have aligned with FDA expectations for the pivotal trial design.

Every participant in OPGx-BEST1's Phase 1/2 Cohort 1 showed functional visual improvement, 75% cleared the FDA-agreed microperimetry bar, and the agency has since aligned on the Phase 3 pivotal design — an unusually clean early-phase package for a rare inherited retinal degeneration with no approved treatment. Whether the thesis pays off depends on a randomized Phase 3 replicating that signal in a structurally larger, blinded trial, where placebo effect and patient heterogeneity are real confounders. The approval path for OPGx-LCA5 carries its own structural fragility: an eight-participant single-arm Phase 3 using natural history as control, a design that FDA scrutinizes closely even under RDEP.